303 results about "Structural protein" patented technology

The invention discloses a high-pathogenicity porcine reproductive and respiratory syndrome virus mRNA vaccine composition and application thereof. The vaccine composition is selected from any one of the following combinations: (1) an mRNA vaccine composition consisting of a PRRSV GP3 mRNA (messenger ribonucleic acid), a PRRSV GP4 mRNA (messenger ribonucleic acid) and a PRRSV GP5 mRNA (messenger ribonucleic acid); or (2) an mRNA vaccine composition consisting of a PRRSV GP5 mRNA, a PRRSV membrane protein (M) mRNA and a PRRSV nucleocapsid protein (N) mRNA. According to the invention, a high-pathogenicity PRRSV JX-A1 strain is used as a template, and mRNAs capable of synthesizing a plurality of fusion proteins GP345, GP5M and GP5MN and single structural proteins GP3, GP4, GP5, M and N are respectively constructed. After liposome encapsulation, mice are inoculated for immunological evaluation, and results show that humoral immunity and cellular immunity levels of a single mRNA-LNPs mixed group are higher than those of recombinant mRNA-LNPs, and GP5 + M + N and GP3 + 4 + 5 have relatively best effects. The invention provides a new technical means for preventing PRRSV (Porcine Reproductive and Respiratory Syndrome Virus).

Provided herein are isolated polynucleotides encoding a polypeptide comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally fused to a ferritin. Also provided herein are isolated polynucleotides encoding alphaviral non-structural proteins nsp1, nsp2, nsp3, and nsp4 and polypeptides comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally fused to a ferritin. The antigen may be influenza. Polynucleotides, such as RNAs, can be used as vaccines against influenza infection.

The invention provides a whole cortical action compound peptide, which comprises acetyl tetrapeptide-11, hexapeptide-9, palmitoyl hexapeptide-12, palmitoyl hexapeptide-14 and / or acetyl hexapeptide-1, and is characterized in that the whole cortical action compound peptide comprises acetyl tetrapeptide-11, hexapeptide-9, palmitoyl hexapeptide-12, palmitoyl hexapeptide-14 and / or acetyl hexapeptide-1; the compound peptide acts on epidermal basal layer keratinocytes, true epidermal junction (DEJ) structural proteins and / or dermal layer fibroblasts, and synergistically exerts a whole-cortex skin anti-aging effect on epidermal layer, basement membrane, dermal layer and / or nerve fibers. The compound peptide has the advantages of full-cortex three-dimensional anti-aging, layered precise targeting, multi-peptide scientific compounding, matrix synergy, clear action mechanism, efficient growth promotion of seven key proteins, remodeling of a true epidermis structure, low-concentration effect, mildness, no stimulation and the like, and is an advanced anti-aging scheme under a precise skin care trend.

The invention discloses an mRNA (messenger ribonucleic acid) transcription skeleton vector and application thereof in preparation of a self-amplification type mRNA vaccine, and belongs to the technical field of veterinary biological products. According to the invention, alphavirus non-structural protein regions NSP2 and NSP3 of a self-amplification type mRNA skeleton are modified, a polyA tail is optimized, and a novel self-amplification type mRNA skeleton is constructed; the self-amplification type mRNA vaccine can improve the antigen expression efficiency, reduce the toxicity of non-structural protein to cells and improve the encapsulation efficiency and delivery efficiency by combining with the optimization of the components and proportion of a lipid nano delivery system, and meanwhile, the self-amplification type mRNA vaccine is wide in applicable pathogen antigen range and can be popularized to more animal epidemic diseases. The characteristics of high-efficiency expression, low-toxicity delivery and single-dose immunization are expected to renovate the immunization strategy of the existing animal vaccine, the epidemic prevention cost of the breeding industry is reduced, and the method has a wide industrial application prospect.

The invention discloses a method for promoting lactobacillus activity enhancement, which comprises the following steps: S1, amplifying a target gene corresponding to an LPxTG structural protein, and amplifying a target gene corresponding to a signal peptide; s2, obtaining a target gene connected with the LPxTG structure and the signal peptide; s3, connecting the target gene obtained in the step S2 with a plasmid gene sequence to construct a recombinant expression vector; s4, introducing the recombinant expression vector obtained in the step S3 into escherichia coli BL-21 so as to increase the number of the recombinant expression vector; s5, introducing the recombinant expression vector obtained in the step S4 into lactobacillus plantarum C8 to obtain a recombinant strain; and step S6, co-culturing lactobacillus plantarum C8 and the recombinant strain obtained in the step S5. The lactobacillus plantarum C8 has the advantages that the whole lactobacillus plantarum C8 and the recombinant strain have better survival condition and adhesiveness in gastric juice and intestinal juice.

The present invention relates to the fields of medicine and cosmetology, and discloses a cell active peptide composition that promotes the regeneration of multi-type collagen structural proteins, its preparation method, and its application in medicine and cosmetology. The composition uses raw materials such as tripeptide-10 citrulline, hexapeptide-9, hydrolyzed sodium hyaluronate, γ-aminobutyric acid, decarboxylated carnosine hydrochloride, acetyl tetrapeptide-3, acetyl tetrapeptide-11, palmitoyl dipeptide-7, and palmitoyl pentapeptide-4. The composition can promote the coordinated expression of skin type I, type III, type IV, type VII, type XVII collagen, fibronectin, elastin, and glycosaminoglycans; prevent collagen cross-linking, maintain triple helix structure, and inhibit collagen degradation. Applied to dermatology and cosmetology, it can accelerate the regeneration of structural proteins such as skin collagen, repair skin damage, reduce wrinkles such as crow's feet, tear groove lines, nasolabial folds, and under-eye lines, solve the skin aging problem caused by the loss of structural proteins such as collagen, and improve skin elasticity and firmness.

The invention belongs to the technical field of mRNA vaccines, and particularly relates to a self-replicating mRNA vaccine as well as a preparation method and application thereof. The self-replicating mRNA is transcribed from an alphavirus skeleton vector, the alphavirus skeleton vector comprises gene sequences of alphavirus non-structural proteins nsP2, nsP3 and nsP4 and mutated nsP1, and cysteine at the 492nd position of the mutated nsP1 is mutated into serine. The self-replicating mRNA provided by the invention has higher expression quantity and longer expression time for the target gene. The self-replicating mRNA is used for expressing IMP3 and can be prepared into a vaccine with good prevention and treatment effects on IMP3 positive tumors. Therefore, the invention has a good application prospect in the development of medicines and vaccines.

The invention discloses an anti-aging and anti-wrinkle composition containing various polypeptides as well as a preparation method and application of the anti-aging and anti-wrinkle composition. According to the anti-aging and anti-wrinkle composition, various polypeptide components are compounded, a synergistic interaction system of the polypeptides is formed, acetyl hexapeptide-8 and snake venom-like peptide are taken as cores, and a dual inhibition pathway is established aiming at dynamic wrinkles; hexapeptide-9 and palmitoyl pentapeptide-4 are compounded to repair a matrix, and regeneration of corium layer structural protein is promoted; with the assistance of mu-conopeptide, palmitoyl tripeptide-1 and palmitoyl tripeptide-5, static wrinkle improvement and skin density improvement are enhanced; and finally, acetyl tetrapeptide-9 is assisted to activate elastin and optimize the contour supporting force, so that the synergistic effect of three effects of resisting wrinkles, tightening and repairing is realized, and the composition has more excellent inhibition rate of elastase and excellent free radical scavenging capacity, and achieves a remarkable antioxidant effect and an excellent anti-aging and anti-wrinkle effect.

The invention relates to an anti-aging composition for strengthening a skin supporting network and application thereof, and the anti-aging composition comprises the following components: a golden camellia flower extract, a saffron crocus extract, camellia seed oil, tranexamic acid and epigallocatechin gallate glucoside, the weight ratio of the golden camellia flower extract to the saffron crocus extract to the camellia seed oil to the tranexamic acid to the epigallocatechin gallate glucoside is (0.1 to 5) to (0.01 to 5) to (0.1 to 10) to (0.01 to 2) to (0.001 to 0.1). The composition provided by the invention can synergistically strengthen a skin support network and comprehensively improve skin elasticity and compactness by promoting growth of two core structural proteins and three macromolecular adhesives of skin, and is mild, non-irritant and suitable for people with sensitive skin.

The invention discloses a variable region amino acid sequence of a monoclonal antibody of a West Nile virus non-structural protein NS1 and application of the variable region amino acid sequence, and belongs to the technical field of medicines. According to the invention, West Nile virus non-structural protein NS1 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the West Nile virus non-structural protein NS1 are screened from rabbit spleen cells through flow sorting, and a signal peptide and a variable region gene fragment of an antibody are cloned through reverse transcription-polymerase chain reaction; according to the present invention, the non-structural protein NS1 of flaviviridae flaviviridae virus is taken as a template, and is connected with a constant region gene to an expression vector, and after mammalian cell expression and purification, the monoclonal antibody which has high affinity and is not combined with the non-structural protein NS1 of other eight viruses of flaviviridae flaviviridae virus is obtained through enzyme-linked immunosorbent assay; the monoclonal antibody has application value in diagnosis and prevention and treatment of West Nile virus infection.

To provide a method for preparing extracellular vesicles from culture medium of microalgae, and to provide a composition containing extracellular vesicles obtained by the method.SOLUTION: A preparation method including filtering a culture supernatant of microalgae, and a composition obtained by such a preparation method are provided. Such an extracellular vesicle-containing composition can be used as a composition for maintaining or increasing a fibrous structural protein.SELECTED DRAWING: Figure 1

The present invention relates to an immunogenic composition and a related vaccine composition comprising one or more nucleic acid(s) encoding structural proteins of Herpes Simplex Virus 2 (HSV-2) or immunogenic fragments thereof. The vaccine composition may be used for the treatment and / or prevention of HSV-2 infection and is particulary beneficial for the immunological control of periodic reactivation of the virus in infected patients.

Alphaviral non-structural protein 3 (nsP3) are provided which are modified at least by a mutation at amino acid position equivalent to amino acid position 167 of wild-type Venezuelan equine encephalitis virus (VEEV) nsP3 of SEQ ID NO:1.

Provided are a replicable RNA molecule and uses thereof, the present invention relates to a replicable RNA molecule comprising, from the 5'end to the 3 'end, a 5' cap, a 5 'UTR, an open reading frame encoding an RNA replicase, a promoter, a sequence of interest, a 3' UTR, and a poly (A) tail wherein the RNA replicase is capable of amplifying the replicable RNA molecule and an RNA molecule containing the sequence of interest and the 3 'UTR wherein the RNA replicase is derived from the group consisting of the group consisting of the MosdPedras virus, MDPV, EVEV, Riogro virus, Mycovirus, Mycovirus, Mycovirus, Mycovirus, Mycovirus, Mycovirus, Mycovirus, Mycovirus, Mycovirus, Mycovirus, Mycovirus and Mycovirus. RnV, Muslim virus, MUCV, Highland J virus, PIXV, TROV, Cabassu virus, TONV, Bebaru virus, BEBV, Formun virus, GETV, or Nnumu virus, and NDUV can be used in the treatment of a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, a disease, and a disease.

The invention provides a PDCoV virus mRNA (messenger Ribonucleic Acid) vaccine capable of self-cleaving and expressing a plurality of virus structural proteins and a preparation method of the PDCoV virus mRNA vaccine, and the vaccine comprises mRNA for expressing S, M and N proteins of a PDCoV virus and LNP for encapsulating the mRNA, and the LNP is marked as SMN-mRNA-LNP. The invention provides a PDCoV mRNA vaccine strategy based on combination of S, M and N for the first time, the S, M and N structural proteins of the PDCoV are connected by using a self-cleavage peptide P2A, the S protein is subjected to double proline mutation, so that a single mRNA can express multiple PDCoV antigens, and a multi-level defense system is constructed by using the neutralizing antibody induction capability of the S protein, the immune regulation function of the M protein and the cellular immune activation characteristic of the N protein. Through evaluation of immunogenicity, antibody level and challenge protection effect of the vaccine in mice, suckling piglets and pregnant sows, a new idea is provided for development of broad-spectrum and efficient PDCoV vaccines, and a practical basis is provided for research and development of coronavirus multi-antigen mRNA vaccines.

Disclosed are vaccine compositions, in particular, polyvalent icosahedral compositions for presentation of an mpox antigen. The disclosed compositions may contain an S particle comprising a norovirus (NoV) S domain protein and an mpox antigen, which may be linked via a linker protein domain operatively connected to the norovirus S domain protein and an mpox antigen. Fusion proteins for producing the vaccine compositions, and methods of using the disclosed vaccine composition are also provided.

The invention discloses a construction method and application of a Uusu figure virus report replicon. According to the invention, a low-copy plasmid pACYC-177B is used as a carrier, all non-structural proteins and non-coding region genes of USUV are retained, 38 amino acids before the N terminal of C protein are retained in the structural protein part, 45 amino acids behind the C terminal of E protein are retained in the structural protein part, and a NanoLuc luciferase tag is inserted between the retained C and E protein genes to obtain a pACYC-TMN-Nlucc-Rep report replicon. The Uu figure virus report replicon pACYC-TMN-Nluc-Rep constructed in the invention can normally work on cells such as BHK21, Vero, DF-1, Hela and the like, and can be effectively translated and replicated. Therefore, the USUV report replicon pACYC-TMN-Nlucc-Rep constructed in the invention can be used as an important research tool to be applied to the research of the USUV.

The invention discloses a porcine reproductive and respiratory syndrome virus mRNA (messenger Ribonucleic Acid) molecule and application thereof, and four mRNA vaccines GP35m-LNP, GP45m-LNP, GP345m-LNP and GP2345m-LNP are designed by combining structural protein GP2a, GP3, GP4 and GP5 genes of a PRRSV FJ1402 strain of NADC30-like. Mouse test results show that the GP345m-LNP can simultaneously induce strong humoral and cellular immune response, the GP2345m-LNP is secondary, and the effect is superior to that of an inactivated vaccine (only inducing humoral immunity). After immunization, the PRRSV FJ1402 strain is adopted for counteracting toxic substances, the virus load in blood and lungs of a GP345m-LNP group is obviously reduced, pathological injuries of the lungs are obviously relieved, the immune effect is superior to that of an inactivated vaccine group, and the vaccine has a relatively good application prospect.

The invention discloses a lactobacillus mucus CCFM1401 for repairing a skin barrier based on multiple target spots and a metagen of the lactobacillus mucus CCFM1401, and belongs to the technical field of microorganisms and medicines. The thallus lysate of the fermented lactobacillus mucus CCFM1401, provided by the invention, can be used for improving the cell viability of damaged keratinocytes and the expression of FLG, LOR, IVL, ZO-1, Occludin and CLDN gene levels in the aspect of external application; and viable bacteria and metabiotics (including thallus lysate and fermentation supernatant) of the fermented lactobacillus mucus CCFM1401 are orally taken, so that TEWL can be reduced, the water content of cuticle can be up-regulated, inflammatory reactions (such as skin histamine and serum IgE) can be reduced, and the skin barrier function and expression of structural protein can be up-regulated. Therefore, the fermented lactobacillus mucilaginosus has a huge application prospect in preparation of external or oral medicines for repairing the skin barrier and preparation of food, health care products or cosmetics.

This invention provides a dengue / Zika virus genetically engineered vaccine and its application. The dengue / Zika virus vaccine comprises an open reading frame encoding envelope protein domain III (EDIII) and the non-structural protein NS1, and displays EDIII monomers in the delivery vector shell. Immunization with this vaccine primarily induces a type-specific antibody response, reducing the production of cross-antibodies and thus effectively avoiding or eliminating the risk of antibody-dependent enhancement of infection (ADE). This vaccine can be used to prevent dengue virus and Zika virus infection.

The application provides a PDCoV virus mRNA vaccine which can be self-cleaved and expresses multiple virus structure proteins and a preparation method thereof, the vaccine comprises mRNA for expressing PDCoV virus S, M and N proteins, and LNP for encapsulating the mRNA, denoted as SMN-mRNA-LNP. The application firstly proposes a PDCoV mRNA vaccine strategy based on S, M and N combination, connects three structure proteins of PDCoV S, M and N by using a self-cleaving peptide P2A, mutates the S protein with double proline, enables a single mRNA to express multiple PDCoV antigens, and utilizes the neutralizing antibody induction ability of the S protein, the immune regulation function of the M protein and the cell immune activation characteristics of the N protein to construct a multi-level defense system. Through evaluation of immunogenicity, antibody level and challenge protection effect of the vaccine in mice, suckling piglets and pregnant sows, a new idea for developing a broad-spectrum and high-efficiency PDCoV vaccine is provided, and practical basis for research and development of a coronavirus multi-antigen mRNA vaccine is provided.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncolytic defective virus compositions and methods of in vivo synthesis thereof. The composition includes a first nucleic acid construct encoding a self-amplifying mRNA (sa-mRNA) encoding at least one gene of interest (GOI) or a plurality of GOIs, a second nucleic acid construct encoding an mRNA encoding at least one virus structural protein, and at least one payload delivery system.

The invention discloses akabane disease virus recombinant virus-like particles and a preparation method thereof, and belongs to the technical field of biology. The akabane disease virus recombinant virus-like particles are obtained by recombinant expression of structural protein Gn and structural protein Gc of akabane disease virus in an insect cell-baculovirus expression system and self-assembly; the amino acid sequence of the structural protein Gn is as shown in SEQ ID NO. 1; the amino acid sequence of the structural protein Gc is as shown in SEQ ID NO. 2. According to the invention, genes of coding structural proteins Gn and Gc are optimized according to codon preference of insect cells, and AKAV virus-like particles with higher safety are successfully prepared through a baculovirus-insect cell expression system. The AKAV virus-like particle provided by the invention has application potential in various fields of AKAV vaccines, immunotherapy and the like, and provides technical reserve for biological safety monitoring.

The invention discloses a DNA vaccine plasmid of a tembusu virus as well as a construction method and application of the DNA vaccine plasmid, and relates to the technical field of molecular biology. The DNA vaccine plasmid of the tembusu virus comprises an expression vector pcDNA3.1-prME containing a 5AA-STING gene segment, and a DNA vaccine plasmid of the tembusu virus, the 5AA-STING gene segment is a gene segment formed by introducing a coding sequence of five amino acids at the N end of the tembusu virus NS1 on an STING gene segment. The invention further provides a construction method and application of the DNA vaccine plasmid of the tembusu virus, the DNA vaccine plasmid of the tembusu virus is favorable for efficiently assembling into a subvirion with a stronger immune effect, and the DNA vaccine plasmid of the tembusu virus can co-express an immune stimulant STING molecule while expressing the structural protein of the tembusu virus to be assembled into the subvirion, so that the DNA vaccine plasmid of the tembusu virus has a good application prospect. The polypeptide is a key molecule for recognizing a double-stranded DNA signal channel in cells, and the immune protection effect is further enhanced.

Disclosed herein are vaccine constructs for producing a virus-like particle (VLP) capable of raising an immune response to an immunogen, and uses thereof, wherein the constructs comprise nucleic acid sequences encoding an immunogen and a polyprotein, wherein the polyprotein comprises two or more viral structural proteins, wherein at least two of the two or more viral structural proteins are separated by a signal peptidase sequence such that, when the polyprotein is expressed in a host cell, the signal peptidase sequence undergoes host cell peptidase-dependent cleavage to liberate the two or more viral structural proteins, thereby allowing the liberated structural proteins to self-assemble into a VLP carrying the immunogen.

The invention discloses a skin barrier repairing oral liquid based on cubilose peptide-collagen-traditional Chinese medicine compounding. The skin barrier repairing oral liquid is prepared from the following raw materials in percentage: 30 to 50 percent of skin nutrition base powder, 5 to 10 percent of three-type collagen peptide, 0.6 to 1 percent of cubilose peptide and 30 to 70 percent of traditional Chinese medicine herbal extract. The three-type collagen peptide disclosed by the invention can be used for directly supplementing key structural protein of a dermis layer of skin, promoting collagen fiber regeneration, improving skin elasticity and reducing fine wrinkles; the cubilose peptide is small in molecular weight, easy to absorb and capable of providing amino acid raw materials for skin cells and enhancing cell activity, the cubilose peptide and the collagen peptide cooperate to solve the problem of insufficient collagen synthesis caused by age increase, the skin nutrient base powder, the collagen peptide and the cubilose peptide are nutrients needed by skin barriers, and the herbal medicine is used for promoting nutrient absorption, mobilizing qi and blood of the body and improving the taste.

The invention relates to the field of biological medicine, and provides a coxsackie virus A16 type mutant and a virus-like particle thereof, compared with a wild type coxsackie virus A16 type, the mutant has at least one amino acid mutation site in the following regions: (1) a canyon region of a virus capsid; (2) a channel area at a secondary axis; or (3) a channel region at a quasi-tertiary axis. The mutant and the virus-like particle are obtained by optimizing and modifying structural proteins VP0, VP1 and VP3 which form a virus capsid by using computational biology and structural biology methods, co-expressing and co-assembling the structural proteins in a hansenula polymorpha expression system to form the virus-like particle, and then carrying out series of chromatographic purification. Compared with a non-mutated coxsackie virus A16 type virus-like particle mutation scheme, the coxsackie virus A16 type virus-like particle mutation scheme disclosed by the invention has the advantages that the antigen immunogenicity can be obviously improved, and the clinical application value is realized.

The present invention provides the preparation, epitope identification and application of a PRRSV non-structural protein 12 antibody. By constructing a eukaryotic expression vector pCDNA3.4-Nsp12-strep, transiently transfecting CHO cells, and purifying the PRRSV Nsp12 recombinant protein using the downstream strep tag, the purified Nsp12 is used as an antigen to immunize Balb / C mice. The spleen cells of the mice are isolated, and single specific B cells are separated by the FACS method. The antibody variable region sequences of the single B cells are obtained by RT-PCR. Recombinant expression plasmids of the heavy chain and light chain are constructed respectively, transfected into CHO suspension cells, expressed, and 2 complete anti-PRRSV Nsp12 monoclonal antibodies 1N14 and 2S18 are obtained by Protein G purification. The application scopes of the 1N14 and 2S18 antibodies and the specific antigen epitope recognized by the 1N14 antibody are further determined, and its sequence is 104 YEFTGNGEDW 113 。

A provided self-replicating mRNA is transcribed from an alphavirus backbone vector. The alphavirus backbone vector comprises gene sequences of alphavirus non-structural proteins nsP2, nsP3, nsP4, and mutated nsP1. A cysteine at position 492 of the mutated nsP1 is mutated into serine. The self-replicating mRNA has a higher expression level and a longer expression time for a target gene. The self-replicating mRNA is used for expressing IMP3, and can be prepared into a vaccine having good preventive and therapeutic effects on IMP3-positive tumors. Therefore, the present invention has good application prospects in drug and vaccine development.

A lipid nanoparticle composition for use in the delivery of a self-amplifying RNA (saRNA) construct in one or more target cells is disclosed. The lipid nanoparticle composition comprises a lipid mixture comprising at least one (ionizable) cationic lipid, at least one helper lipid, a sterol, a corticosteroid such as Dexamethasone, and a least one lipid-polyethylene glycol conjugate. The saRNA construct comprises a first open reading frame which encodes one or more non-structural proteins, and a second open reading frame operatively linked to the first open reading frame. The second open reading frame comprises a coding region which encodes one or more target proteins. In some embodiments, the target proteins comprise one or more therapeutic proteins. In some embodiments, the target proteins comprise one or more one or more Cas proteins and / or variants thereof for use in CRISPR-based gene editing.